AHB(SH:688639) Zheng Quan Zhi Xing·2025-09-04 16:17Core Viewpoint - Anhui Huaheng Biological Technology Co., Ltd. plans to issue H shares and apply for listing on the Hong Kong Stock Exchange to enhance its global development strategy, brand influence, and core competitiveness [1][2]. Group 1: Board Meeting Details - The fourth board meeting was held on September 4, 2025, with all 9 directors present, ensuring compliance with legal and regulatory requirements [1]. - The board unanimously approved the proposal for issuing H shares and listing on the Hong Kong Stock Exchange, which will be submitted to the shareholders' meeting for further review [2]. Group 2: H Share Issuance Plan - The H shares will be ordinary shares with a nominal value in RMB, available for subscription in foreign currency, with a maximum issuance not exceeding 15% of the total share capital post-issuance [3][4]. - The issuance will include both a public offering in Hong Kong and an international placement, targeting qualified institutional investors [2][5]. Group 3: Fund Utilization Plan - The funds raised from the H share issuance will be used for global expansion, development of synthetic biology technologies, capacity upgrades, and general corporate purposes [8][9]. - The board will have the authority to adjust the specific use of funds based on regulatory feedback and operational needs [9]. Group 4: Corporate Structure Changes - Following the H share issuance, the company will transition to a publicly listed company in both Shanghai and Hong Kong, becoming a foreign-funded company [10]. - The board approved the cancellation of the supervisory board, with its functions to be assumed by the audit committee [16]. Group 5: Governance and Compliance - The board will appoint various professional intermediaries for the H share issuance, ensuring compliance with Hong Kong regulations [7][8]. - The company will revise its articles of association to align with the new corporate structure and regulatory requirements post-listing [18]. Group 6: Shareholder Engagement - A second extraordinary general meeting will be convened in 2025 to discuss the proposals approved by the board [18]. - The board has proposed a profit distribution plan for retained earnings prior to the H share issuance, ensuring equitable treatment for existing and new shareholders [12].